KCT0000452已完成未知
Phase II Randomized, Double-Blind Study of JINIS JBD301 in Obese Adults
JINIS Biopharmaceuticals0 个研究点目标入组 110 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 65(Year)（—）
- 性别
- All
入选标准
- •1) Written informed consent
- •2) Men and women between 20-65 years of age
- •3) Body mass index between 25 ~ 35kg/m2
排除标准
- •1) Subjects who have received antibiotics within 12 week prior to the first visit
- •2) Subject with current use of medications for body weight reduction (lipase inhibitor, anti-depressants, appetite suppressant), diuretics, contraceptives, steroids, and hormones
- •3) Subjects who have been involved in commercial diet programs or under diet formula within 12 weeks prior to the first visit
- •4) Subjects with uncontrolled hypertension or diabetes
- •5) Subjects with current medical conditions, including cardiac, renal, hepatic, neurovascular, thyroid and parathyroid disorders/diseases
- •6) Subjects with medical conditions, including depression, schizophrenia, psychosis, alcohol abuse and drug abuse
- •7) Subjects diagnosed with cancer within 5 years
- •8) Subjects with hyper-allergic conditions to components in the testing food
- •9) Subjects who is planning to reduce body weight by food and exercise during the clinical trial period
- •10) Subject with current pregnancy or breast feeding
- •11) Subject is otherwise unsuitable for the study, in the opinion of the investigator
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced Pancreatic CancerAdvanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapyMedDRA version: 18.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2014-000294-39-NLIncyte Corporation270
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced Pancreatic CancerAdvanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapyMedDRA version: 17.1Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2014-000294-39-SEIncyte Corporation270
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced Pancreatic CancerAdvanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapyMedDRA version: 17.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2014-000294-39-FRIncyte Corporation270
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced Pancreatic CancerEUCTR2014-000294-39-ATIncyte Corporation270
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced Pancreatic CancerAdvanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapyMedDRA version: 17.1Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2014-000294-39-DKIncyte Corporation86